Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
EUCR was delisted on the 26th of April, 2023.
34 hedge funds and large institutions have $49.6M invested in Eucrates Biomedical Acquisition Corp. Ordinary Shares in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
10% more funds holding
Funds holding: 31 → 34 (+3)
4% more capital invested
Capital invested by funds: $47.8M → $49.6M (+$1.81M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$780K |
| 2 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$765K |
| 3 |
SIA
SkyView Investment Advisors
Shrewsbury,
New Jersey
|
+$648K |
| 4 |
D.E. Shaw & Co
New York
|
+$533K |
| 5 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
+$324K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$985K |
| 2 |
EAM
Exos Asset Management
New York
|
-$103K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$98K |
| 4 |
SC
Shay Capital
New York
|
-$69.6K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$50.4K |
EUCR Hedge Fund Activity: Q3 2021 in Review
34 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) for Q3 2021, worth a combined $49.6M — up 3.8% from $47.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new EUCR positions and 3 closed out — a net gain of 3 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, adding an estimated $780K. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $985K sold.
- 34 institutional investors held Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) as of Q3 2021, up from 31 in Q2 2021.
- Funds reported $49.6M of Eucrates Biomedical Acquisition Corp. Ordinary Shares stock for Q3 2021, up 3.8% quarter-over-quarter.
- 6 funds opened new Eucrates Biomedical Acquisition Corp. Ordinary Shares positions in Q3 2021 and 3 closed out, a net change of +3 holders.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares buyer in Q3 2021 was Millennium Management, an estimated $780K added.
- The largest Eucrates Biomedical Acquisition Corp. Ordinary Shares seller in Q3 2021 was Granite Point Capital Management, an estimated $985K sold.
Based on aggregated 13F filings for Q3 2021.